Objective
to assess the efficacy of paclitaxel-coated balloons (PCB) versus polymer-coated paclitaxel-eluting stents (PES) for the treatment of complex femoropopliteal lesions (CFL)
Study
prospective, multicentre, randomised pilot trial
Population
CFL: Rutherford classification 2-4, mean lesion length 187.7 ± 78.3 mm, 79.2% total occlusion
Endpoints
primary patency at 12 months, defined as absence of clinically-driven target lesion revascularisation or restenosis
/medias/687735/25-T014_Wittig_01.jpg)
/medias/687738/25-T014_Wittig_02.jpg)
Conclusion
amongst patients with complex femoropopliteal lesions, treatment with paclitaxel-coated ballons or paclitaxel-eluting stents was not different and both associated with high primary patency rates at 12 months
Wittig et al., J Am Coll Cardiol Intv, 2024; 17:1134-1144
